Form 4: Major Investor Versant Ventures Sells Over 330,000 Shares of LENZ Therapeutics

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, Inc., reported the sale of 334,801 shares of common stock in mid-June 2025.

Summary

• Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P., and Versant Vantage II, L.P., along with their general partners and managing entities (collectively "Versant Entities"), reported sales of LENZ Therapeutics, Inc. common stock.
• The Versant Entities are identified as a 10% owner and director of LENZ Therapeutics.
• On June 18, 2025, 100,000 shares were sold at $29.95 per share.
• On June 20, 2025, two separate transactions occurred: 100,877 shares were sold at $30.35 per share, and 133,924 shares were sold at $30.25 per share.
• In total, 334,801 shares of LENZ common stock were sold across these transactions.
• Following these transactions, Versant Venture Capital VII, L.P. indirectly holds 1,047,912 shares, Versant Venture Capital VI, L.P. directly holds 1,967,275 shares, and Versant Vantage II, L.P. indirectly holds 842,162 shares.

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a major institutional investor and director is generally perceived negatively by the market, indicating a potential lack of confidence or a move to realize gains.

Negatives

• Significant insider selling by a major institutional investor and director, Versant Venture Capital, which could signal a lack of confidence in the company's near-term prospects or valuation.
• The sale of 334,801 shares represents a notable reduction in their holdings.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.
• Reduced alignment of interests between a significant institutional investor/director and common shareholders.

Future Outlook

NA

Industry Context

This filing is specific to insider trading and does not provide broader industry context. However, in the biotech/pharma sector, insider selling by venture capital firms can sometimes precede or coincide with clinical trial results or regulatory decisions, though no such context is provided here.

Related Party Transactions

• The reported sales of common stock by Versant Venture Capital entities are considered related party transactions as Versant is a 10% owner and has a director relationship with LENZ Therapeutics, Inc.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Employees: No direct impact mentioned, but a declining stock price could affect equity-based compensation.

Key Dates

Recommendation

Keywords

LENZ Therapeutics, LENZ, Versant Venture Capital, insider selling, Form 4, beneficial ownership, stock sale, institutional investor, director, equity